The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / IV Tramadol Promising for Postoperative Pain; FDA Denies IV Meloxicam Approval

IV Tramadol Promising for Postoperative Pain; FDA Denies IV Meloxicam Approval

July 2, 2018 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In its first phase 3 clinical trial, intravenous (IV) tramadol has met its primary endpoint for relieving postoperative pain. In other news, the U.S. Food and Drug Administration (FDA) did not approve a new drug application for IV meloxicam.

You Might Also Like
  • Recro Pharma’s Non-Opioid Pain Shot Fails to Get Approval from FDA
  • The FDA Denies Approval for Remoxy Extended Release; Plus Knee OA Pain Treatment Moves into Phase 3 Trials
  • IV Meloxicam Stalls at FDA; Plus Health Canada Approves Risankizumab for Plaque Psoriasis
Explore This Issue
August 2018
Also By This Author
  • FDA Responds to New Drug Application for Baricitinib

Intravenous Tramadol in Phase 3 Clinical Trials
In its first phase 3 clinical trial, intravenous (IV) tramadol has met its primary endpoint, achieving a statistically significant improvement in the Sum of Pain Intensity Difference over 48 hours.1 This trial was a multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of IV tramadol for postoperative pain.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

These primary endpoint results were compared with placebo in patients with moderate to severe postoperative pain post-bunionectomy (N=409). Secondary trial endpoints were also met. These include SPID24, total rescue medicine consumption and Patient Global Assessment (P<0.01; for all three compared with placebo-treated patients). Additionally, IV tramadol showed a clear dose response.

During the study, patients were randomized to a postoperative regimen of 50 mg IV tramadol, 25 mg IV tramadol or placebo given over 15 minutes at Hours 0, 2 and 4. Dosing was also given once every four hours thereafter for up to 13 doses in a 1:1:1 ratio. Statistically significant improvement in pain reduction occurred as early as 30 minutes after dosing, which was the first assessment time.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

IV tramadol was generally well tolerated by patients, with adverse events being mostly mild to moderate in severity. The most common adverse events differing from placebo-treated patients were dizziness, nausea, somnolence and vomiting. No reports of serious adverse events were made. One patient treated with 50 mg IV tramadol discontinued the trial due to vomiting.

A second phase 3 trial in a postsurgical population is planned for the second half of 2018.

IV Meloxicam Denied FDA Approval
Meloxicam is a long-acting, non-steroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclo-oxygenase-2 (COX-2).2 IV meloxicam has completed two phase 3 clinical trials examining efficacy. Additionally, it has undergone a large double-blind, placebo-controlled, phase 3 safety trial and four phase 2 clinical efficacy trials. In these studies, the treatment demonstrated statistically significant outcomes of the primary endpoints studied.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

On May 24, the investigating manufacturer of IV meloxicam received a complete response letter from the FDA stating that, although the study results were positive, the FDA did not approve the treatment’s application in its current form. The FDA letter also stated that data from ad hoc analyses and selective secondary endpoints suggest the analgesic effect of IV meloxicam did not meet the FDA’s expectations. Other questions were also raised related to data provided in the new drug application.

Pages: 1 2 | Single Page

Filed Under: Analgesics, Drug Updates Tagged With: FDA, FDA approval, meloxicam, nonsteroidal antiinflammatory drug (NSAID), Pain, post-surgery, tramadol, U.S. Food and Drug Administration (FDA)Issue: August 2018

You Might Also Like:
  • Recro Pharma’s Non-Opioid Pain Shot Fails to Get Approval from FDA
  • The FDA Denies Approval for Remoxy Extended Release; Plus Knee OA Pain Treatment Moves into Phase 3 Trials
  • IV Meloxicam Stalls at FDA; Plus Health Canada Approves Risankizumab for Plaque Psoriasis
  • Revised Application Expected for IV Meloxicam; Plus EU Approves Tildrakizumab

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)